Ziogas Dimitrios C, Terpos Evangelos, Dimopoulos Meletios A
a Department of Clinical Therapeutics , Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine , Athens , Greece.
Leuk Lymphoma. 2017 Apr;58(4):781-787. doi: 10.1080/10428194.2016.1246729. Epub 2016 Nov 28.
In the current evolving landscape of myeloma therapies, no recommended salvage strategy exists for patients with relapsed multiple myeloma (MM) after initial successful autologous stem cell transplantation (ASCT) and therapeutic options extend from conventional chemotherapy and novel agents to second autologous and allogeneic transplants. In this article, we summarize the documented evidence about the utilization of second ASCT in patients with relapsed MM after a primary auto-graft and discuss the correct timing for such a salvage approach, the individual characteristics of patients who will benefit more, as well as the therapeutic role of second ASCT in the modern era of forthcoming anti-myeloma treatments.
在当前不断发展的骨髓瘤治疗格局中，对于初次成功进行自体干细胞移植（ASCT）后复发的多发性骨髓瘤（MM）患者，尚无推荐的挽救策略，治疗选择范围从传统化疗和新型药物到第二次自体及异基因移植。在本文中，我们总结了关于原发性自体移植后复发的MM患者使用第二次ASCT的已记录证据，并讨论了这种挽救方法的正确时机、将更多获益的患者个体特征，以及在即将到来的抗骨髓瘤治疗的现代时代第二次ASCT的治疗作用。
